Richard Garr

20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020

The-Niche-stem-cell-predictions-2020

Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for …

20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020 Read More »

Critical new piece on MD Stem Cells purported Right To Try program: let’s dig into it

Steven-Levy-Jeffrey-Weiss

I’ve been concerned about a stem cell group called MD Stem Cells for many years. Now it comes under more scrutiny from a new must-read piece by Donna Young over at S&P Global. Young’s article reports a puzzling, purported right-to-try (RTT) program that MD Stem Cells appears to working on with Richard Garr. Note that …

Critical new piece on MD Stem Cells purported Right To Try program: let’s dig into it Read More »

Weekend reads: stem cells, CRISPR, glioma, stroke, RTT & more

Venkatesh-et-al.-Nature-2019-Fig-2e

Every so often I realize I’ve accumulated a bunch of tabs on my browsers of things I need to dive into as time permits, which sometimes translates into a collection of recommended reads here on The Niche. Here are some recommended recent reads in the stem cell/regenerative medicine field and childhood cancer space. It includes …

Weekend reads: stem cells, CRISPR, glioma, stroke, RTT & more Read More »

Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope

NSRichard08-headshot

A new right-to-try company called Beacon of Hope is stirring some intense discussion. State and federal right-to-try laws could potentially change the fabric of how many investigational studies are conducted. That may happen through firms like Beacon of Hope. However, we don’t know much about the firm. I’m hoping to help change that. Today’s post …

Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope Read More »

Meeting review of unique stem cell ethics symposium @UCDAVIS

Stem-cell-ethics-meeting-e1479769073498

On Thursday here at UC Davis School of Medicine we held our second annual Stem Cell Ethics Symposium. The symposium was organized by Drs. Mark Yarborough and Nanette Joyce as well as me. In this post I report on key take homes from the meeting and summarize the specific talks. As far as I know, this is one of the few …

Meeting review of unique stem cell ethics symposium @UCDAVIS Read More »

UC Davis 2nd Annual Stem Cell Ethics Symposium: Save the Date Feb. 12

stem-cell-ethics

We here at UC Davis School of Medicine are gearing up for our 2nd annual Stem Cell Ethics Symposium (see flyer). As one of the organizers, I’m really excited about our lineup of speakers including Timothy Caulfield, Leigh Turner, Alison Sorkin, Mary Ann Chirba, and Richard Garr as well as others. We will be focusing …

UC Davis 2nd Annual Stem Cell Ethics Symposium: Save the Date Feb. 12 Read More »

Interview with Neuralstem CEO Richard Garr

I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting?  Garr: Neuralstem is moving on all cylinders these days on …

Interview with Neuralstem CEO Richard Garr Read More »